Navigation Links
Tengion Provides Business Update and Reports Second Quarter 2011 Financial Results
Date:8/9/2011

EAST NORRITON, Pa., Aug. 9, 2011 /PRNewswire/ -- Tengion, Inc. (Nasdaq: TNGN) today provided a business update and reported its financial results for the second quarter ended June 30, 2011.

"This is an important time for Tengion as we continue to make progress on our lead clinical and preclinical programs, as well as on our corporate and partnership strategy," said David Scheer, chairman of the Tengion board of directors. "Our search for a new chief executive officer is underway and our dialogue with the FDA is ongoing as we continue to advance our Neo-Urinary Conduit clinical trial. We expect to provide more updates in the near term as we execute on our overall strategy."

Neo-Urinary Conduit Bladder Cancer Trial – Clinical UpdateTengion is currently conducting an initial clinical trial of its lead product candidate, the Neo-Urinary Conduit™, for use in bladder cancer patients requiring a urinary diversion following bladder removal (cystectomy).  The Neo-Urinary Conduit is a combination of a patient's own cells and bioabsorbable scaffold that is intended to catalyze regeneration of a native bladder tissue conduit, passively transporting urine from the ureters through a stoma, or hole in the abdomen, into a standard ostomy bag.  Patients requiring some form of urinary diversion with today's standard of care, the use of a segment of bowel tissue to construct a conduit for urine to exit from the body into an ostomy bag, are at risk of complications associated with the use of bowel tissue as well as those associated with the surgery to harvest the bowel tissue.

The trial is designed to assess the safety and preliminary efficacy of the Neo-Urinary Conduit, as well as to allow the clinical investigators to optimize the surgical procedure and post-surgical care by incorporating the outcomes observed in each patient into the surgical approach f
'/>"/>

SOURCE Tengion, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Tengion Announces Leadership Transition
2. Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
3. Tengion to Host Conference Call to Provide a Business Update and Report First Quarter 2011 Financial Results on May 12, 2011
4. Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel
5. Tengion To Host Conference Call To Provide a Business Update and Report Fourth Quarter 2010 Financial Results on March 25, 2011
6. Tengion Announces Pricing of $31.4 Million Private Placement
7. Tengion Addresses Recent Trading Activity in its Common Stock
8. Tengion to Present at the 13th Annual BIO CEO & Investor Conference and the Leerink Swann Hot Topics in Therapeutics Roundtable Conference
9. Tengion Presents New Large Animal Data Demonstrating Functional Kidney Regeneration at the American Society for Transplantation Annual Conference
10. Tengion Appoints Richard E. Kuntz, MD to its Board of Directors
11. Tengion Announces Webcast of Analyst and Investor Meeting on October 27, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... DIEGO , July 29, 2014   Sequenom, ... sciences company that provides innovative genetic analysis solutions, and ... of esoteric laboratory services in the United ... noninvasive prenatal testing patents and applications. "We ... innovation, and patient care, and we welcome the opportunity ...
(Date:7/29/2014)... Can a particle be separated from its properties? On ... published the results of the first Cheshire Cat experiment, ... Chapman University in Orange, CA, and Vienna University of ... without a grin," thought Alice in Wonderland, "but a ... I ever saw in my life!" Alice,s surprise stems ...
(Date:7/29/2014)... researchers has created a new way of manufacturing ... surfaces, made by self-assembly of carbon nanotubes, could ... controllable mechanical stiffness and strength, or the ability ... "We have demonstrated that mechanical forces can be ... microstructures, and that we can independently control ...
(Date:7/29/2014)... , July 29, 2014  Pomerantz LLP is ... Inc. ("Impax" or the "Company") (NASDAQ: IPXL).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... its officers and/or directors have violated Sections 10(b) and ... On July 29, 2014, Impax Laboratories, Inc. ...
Breaking Biology Technology:Sequenom Enters Into License Agreement With Mayo Medical Laboratories 2Sequenom Enters Into License Agreement With Mayo Medical Laboratories 3Sequenom Enters Into License Agreement With Mayo Medical Laboratories 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4A new way to make microstructured surfaces 2SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2
... KALAMAZOO, Mich., Oct. 28 Stryker Corporation (NYSE: SYK ... District of Massachusetts has returned an indictment charging Stryker Biotech ... with wire fraud, conspiracy to defraud the U.S. Food and ... statements to the FDA. The Company disclosed in March of ...
... INCLINE VILLAGE, Nev., Oct. 28 PDL BioPharma, Inc. ... has priced a $300 million securitization transaction intended to ... , Upon closing of the transaction, which is expected ... sell to QHP Royalty Sub LLC ("QHP"), a newly-formed ...
... , GAITHERSBURG, Md., Oct. 28 GenVec, Inc. (Nasdaq: ... the third quarter ended September 30, 2009 on Thursday, November ... call at 10:00 a.m. EST on Friday, November 6, 2009 ... http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ) , To listen to ...
Cached Biology Technology:Stryker Statement in Response to the Indictment of Its Biotech Division 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 3GenVec Announces Third Quarter 2009 Results Conference Call 2
(Date:7/30/2014)... pledge of $1 million from the Cornelia Cogswell Rossi ... Biometry Center. , The newly established Connie ... to develop a greater breadth and depth of knowledge ... the pace of research to improve human health. , ... for the Laboratory and its external partners, supporting research ...
(Date:7/30/2014)... July 30, 2014 ResearchMoz ... Government Biometric Systems Market 2014-2024   Business Strategies, Industry ... Biometric Systems Market 2014-2024" offers the reader detailed ... the next ten years, alongside potential market opportunities ... forecasts. To view the table of ...
(Date:7/30/2014)... across-the-board increase in Impact Factors for its molecular ... Reports (Thomson Reuters, 2014) show that Clinical ... in Biochemistry , Biochemical Society Transactions ... in their Impact Factors. The journals are owned ... Press Limited. , 2014 Impact Factors (2013 Impact ...
Breaking Biology News(10 mins):Rossi Foundation pledges $1M for JAX neurobehavioral research center 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 2Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 3Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 4Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 5Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 6Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 7Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 8Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 9Global Government Biometric Systems Market Size, Share, Trends and Forecasts 2014-2024 Available Online by Researchmoz.us 10Across-the-board Impact Factor increases for Portland Press Limited 2
... / b3c newswire / - Kinaxo Biotechnologies GmbH has ... identify the protein kinase mTOR as a new ... a non-steroidal, anti-inflammatory Cox-2 inhibitor approved for the ... In addition, celecoxib’s anti-proliferative effect has earned it ...
... of memories for a lifetime. But when our eyes ... also creates temporary memories that help us process complex ... For decades, scientists have held that such short-term memories ... the course of several seconds. Now researchers at ...
... of healthy people can cause serious infections in premature ... university Karolinska Institutet have now found an explanation for ... to the skin and quickly develop dynamic ecosystems: the ... establishes itself on the child,s skin and mucous ...
Cached Biology News:KINAXOs Cellular Target Profiling reveals mTOR as a new target of Celebrex 2Some short-term memories die suddenly, no fading 2Tufted bacteria cause infection in premature babies 2
Recombinant Feline IL-2, CF...
Recombinant Equine IL-4, CF...
Recombinant Rat Leptin, CF...
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: